Related references
Note: Only part of the references are listed.Gene-expression Profiling - A Decision Impact Analysis: Decision Dependency on Oncotype DX® as a Function of Oncological Work Experience in 117 Cases
Christian Eichler et al.
ANTICANCER RESEARCH (2019)
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
J. A. Sparano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer A Secondary Analysis of a Randomized Clinical Trial
Lvana Sestak et al.
JAMA ONCOLOGY (2018)
Breast cancer histopathology is predictive of low-risk Oncotype Dx recurrence score
Parker C. Wilson et al.
BREAST JOURNAL (2018)
Human Bocavirus Infection of Permanent Cells Differentiated to Air-Liquid Interface Cultures Activates Transcription of Pathways Involved in Tumorigenesis
Verena Schildgen et al.
CANCERS (2018)
Reproducibility in Cancer Biology: Making sense of replications
Brian A. Nosek et al.
ELIFE (2017)
MammaPrint versus EndoPredict: Poor correlation in disease recurrence risk classification of hormone receptor positive breast cancer
Andreas Boesl et al.
PLOS ONE (2017)
Correlation of Oncotype DX Recurrence Score with Histomorphology and Immunohistochemistry in over 500 Patients
Matthew G. Hanna et al.
INTERNATIONAL JOURNAL OF BREAST CANCER (2017)
Intratumor Heterogeneity Affects Gene Expression Profile Test Prognostic Risk Stratification in Early Breast Cancer
Rekha Gyanchandani et al.
CLINICAL CANCER RESEARCH (2016)
Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy
Richard Buus et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Comprehensive Histologic Scoring to Maximize the Predictability of Pathology-generated Equation of Breast Cancer Oncotype DX Recurrence Score
Thaer Khoury et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2016)
Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy
Richard Buus et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
A Prospective Comparison of the 21-Gene Recurrence Score and the PAM50-Based Prosigna in Estrogen Receptor-Positive Early-Stage Breast Cancer
Michael D. Alvarado et al.
ADVANCES IN THERAPY (2015)
Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens
Torsten Nielsen et al.
BMC CANCER (2014)
An open investigation of the reproducibility of cancer biology research
Timothy M. Errington et al.
ELIFE (2014)
Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement
H. A. Azim et al.
ANNALS OF ONCOLOGY (2013)
A simple and reproducible breast cancer prognostic test
Luigi Marchionni et al.
BMC GENOMICS (2013)
Multigene Assays for Classification, Prognosis, and Prediction in Breast Cancer: a Critical Review on the Background and Clinical Utility
P. Sinn et al.
GEBURTSHILFE UND FRAUENHEILKUNDE (2013)
Decentral gene expression analysis: analytical validation of the Endopredict genomic multianalyte breast cancer prognosis test
Ralf Kronenwett et al.
BMC CANCER (2012)
Estrogen Receptor (ESR1) mRNA Expression and Benefit From Tamoxifen in the Treatment and Prevention of Estrogen Receptor-Positive Breast Cancer
Chungyeul Kim et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Respiratory Infections by HMPV and RSV Are Clinically Indistinguishable but Induce Different Host Response in Aged Individuals
Vanessa Ditt et al.
PLOS ONE (2011)
Human Epidermal Growth Factor Receptor 2 Assessment in a Case-Control Study: Comparison of Fluorescence In Situ Hybridization and Quantitative Reverse Transcription Polymerase Chain Reaction Performed by Central Laboratories
Frederick L. Baehner et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Estrogen- and progesterone-receptor status in ECOG 2197: Comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory
Sunil S. Badve et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Predicting response to primary chemotherapy: gene expression profiling of paraffin-embedded core biopsy tissue
Lida Mina et al.
BREAST CANCER RESEARCH AND TREATMENT (2007)
Analytical validation of the oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer
Maureen Cronin et al.
CLINICAL CHEMISTRY (2007)
Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes
MA Cobleigh et al.
CLINICAL CANCER RESEARCH (2005)
Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy
FJ Esteva et al.
CLINICAL CANCER RESEARCH (2005)
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
S Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Measurement of gene expression in archival paraffin-embedded tissues - Development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay
M Cronin et al.
AMERICAN JOURNAL OF PATHOLOGY (2004)